Recent News

• 03.31.2026 - Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology
• 03.02.2026 - Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors
• 02.24.2026 - Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
• 02.23.2026 - Apellis Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference
• 02.19.2026 - Apellis Announces Eight Oral Presentations at the 49th Macula Society Annual Meeting
• 02.10.2026 - Apellis Pharmaceuticals to Host Conference Call on February 24, 2026, to Discuss Fourth Quarter and Full Year 2025 Financial Results

Recent Filings

• 03.26.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 03.13.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.03.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.03.2026 - 3 Initial statement of beneficial ownership of securities
• 03.02.2026 - 8-K Current report
• 02.24.2026 - S-8 Securities to be offered to employees in employee benefit plans
• 02.24.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 02.17.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 02.13.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.11.2026 - 144 Report of proposed sale of securities